Hepatic regimen-related toxicity (RRT) is a serious complication of stem cell transplantation. Cytokine activation may be involved in the pathogenesis. Corticosteroids are potent inhibitors of cytokine production, and, therefore could play a role in the treatment of hepatic RRT. Between January 1994 and June 1998, 28 of 782 consecutive transplant patients (3.6%) developed hepatic RRT (20 veno-occlusive disease (VOD) and eight liver dysfunction of uncertain etiology (LDUE) as defined by Seattle criteria), and were treated with highdose methylprednisolone (MP, 500 mg/m 2 i.v. every 12 h for six doses), initiated upon increase in serum total bilirubin to у4 mg/dl. Other causes of liver dysfunction were excluded. Response to therapy with high-dose MP was defined as reduction in total bilirubin by 50% within 10 days of initiation of MP. Overall, 17 patients (61%) responded to treatment (12 patients with VOD, five patients with LDUE). The bilirubin in responding patients decreased from a mean of 8.6 mg/dl (range, 4-17.9) at the start of MP to 4.1 mg/dl (range, 0.5-17.9) 10 days later. There were no statistically significant differences between responders and non-responders in the day treatment with high-dose MP was initiated (P = 0.38), total serum bilirubin (P = 0.17) and percent weight gain at the time high-dose MP was started (P = 0.10) or the calculated probability of fatal outcome from VOD (18% for responders, 23% for non-responders; P = 0.30). A lower pre-transplant DLCOc was observed among non-responders (P = 0.04). At 100 days posttransplant, hepatic RRT resolved in all 13 survivors who responded to high-dose MP, and in one nonresponding patient. No serious toxicities due to highdose MP were observed. We conclude that resolution of hepatic RRT occurred in the majority of patients treated with high-dose MP in this study; however, randomized controlled trials are required to determine the efficacy of high-dose MP for treatment of hepatic RRT. Hepatic regimen-related toxicity (RRT) is a serious complication of high-dose therapy and stem cell transplantation, and is usually diagnosed by clinical findings.
Hepatic regimen-related toxicity (RRT) is a serious complication of high-dose therapy and stem cell transplantation, and is usually diagnosed by clinical findings. 1 Veno-occlusive disease (VOD) is defined as hyperbilirubinemia (total serum bilirubin Ͼ2 mg/dl) associated with either one 2 or two 3 of the following signs: hepatomegaly or right upper quadrant pain of liver origin, weight gain or ascitis. Patients who meet only one of the criteria for VOD (ie jaundice or fluid retention with no identifiable cause), are considered to have liver dysfunction of uncertain etiology (LDUE). 1, 4 The histologic correlates of the syndrome of VOD include central vein occlusion, zone 3 hepatocyte necrosis and sinusoidal fibrosis. 5 The precise sequence of pathogenic events leading to the clinical presentation of VOD is unknown, but hypotheses have been generated which assist in the design of treatment strategies for management of this complication. Cytokine activation, alterations in coagulation proteins, and other cellular events are potential causative factors and are all secondary to the toxic effects of conditioning therapy. 1 Damage to hepatocytes may be initiated by therapy-induced depletion of glutathione levels, an insult that may be prevented in pre-clinical models by pre-treatment with glutathione (-like) substrates. [6] [7] [8] [9] [10] Cytokines may be involved as mediators of the pathogenesis of VOD. 11 Tumor necrosis factor ␣ (TNF␣) levels increase during administration of dose-intense therapy, and correlate with the likelihood of subsequent development of major complications of transplant, 12 including VOD. 11, 13 TNF␣ mRNA expression by blood mononuclear cells increases before the onset of VOD. 14 TNF␣ increases the production of plasminogen activator inhibitor-1 (PAI-1) 15, 16 by endothelial cells. Recent data suggest that the PAI-1 level in blood is a sensitive and specific marker for the diagnosis of VOD. 17 In response to cell injury or certain cytokines, specifically interleukin-1 and TNF␣ activated endothelial cells also release tissue factor 18, 19 and von Willebrand factor. 20 The procoagulant effect of these events may explain the frequent histologic finding of fibrin and factor VIII within the central veins and in the adjacent sinusoids. 21, 22 As VOD progresses, fibrous obliteration of terminal hepatic venules and small lobular veins occurs presumably due to deposition of type I and III collagen. 23, 24 Because approximately half of patients with VOD ultimately recover spontaneously, treatment is primarily supportive. 25 Uncontrolled studies of thrombolysis using recombinant tissue plasminogen activator (tPA), the physiologic antagonist of PAI-1, with heparin showed evidence of efficacy in approximately one-third of patients with severe VOD, 26, 27 but was associated with a high risk of serious bleeding. 27 Corticosteroids are potent inhibitors of cytokine production, 28, 29 and therefore could play a role in the treatment of VOD. To test this hypothesis, we prospectively treated stem cell transplant patients who developed hepatic RRT with high-dose methylprednisolone (MP) to determine the proportion of responding patients, to ascertain whether response to high-dose MP could be predicted, and to evaluate the safety of high-dose MP in this setting.
Materials and methods

Patient selection
Since January 1994, marrow transplant recipients who developed hyperbilirubinemia in the immediate post-transplant setting, were consistently evaluated, managed and treated. A work up to exclude other causes of liver dysfunction which could be confused with hepatic RRT was initiated for an elevation of serum total bilirubin Ͼ2 mg/dl. This evaluation included, besides physical examination, hepatitis serology panel, routine and fungal blood cultures, and liver sonography. Allogeneic transplant recipients were evaluated for clinical, and if appropriate, histologic evidence of graft-versus-host disease (GVHD). Other tests were performed, if indicated. Liver biopsy and measurement of hepatic venous pressure gradient were not routinely performed due to the bleeding tendency of this patient population. Fractional excretion of sodium was also not routinely obtained, as this calculation may be altered by the routine administration of diuretics to keep patients euvolemic and at their baseline pretransplant weight. VOD and LDUE were defined clinically according to the Seattle criteria. 2 
Management
All patients with hepatic RRT received, as needed, supportive care including diuretics for fluid retention and narcotics for painful hepatomegaly. Complications of severe hepatic insufficiency or failure, such as encephalopathy and bleeding, were managed by standard medical practice.
Treatment
High-dose MP was started after the diagnosis of VOD or LDUE and when serum bilirubin equaled or exceeded 4 mg/dl. Patients gave informed consent in accordance with the Institutional Review Board of Washington University School of Medicine. MP was administered at a dose of 500 mg/m 2 intravenously every 12 h for a total of six doses. The daily dose of MP was then decreased to 2 mg/kg for 3 days and tapered off, or if applicable, to the pre-highdose MP steroid regimen. Concurrent therapy with tPA, streptokinase or PGE1 was not permitted unless evidence of progressive VOD was present 3 days after the completion of high-dose MP.
Patient monitoring
Patients were monitored daily for liver size or tenderness, presence or absence of edema or ascites, body weight and urine output, total serum bilirubin, serum creatinine, alkaline phosphatase, sGOT and sGPT. Four times a day blood glucose and daily surveillance blood cultures were obtained while patients received high-dose MP. Insulin was administered, as needed, for hyperglycemia.
Definition of response
Response to high-dose MP was defined similarly to the recently published criteria used by Bearman et al, 27 ie a reduction by 50% of serum bilirubin within 10 days of initiation of high-dose MP. Diuresis and weight reduction were not used in the evaluation of response because concurrent supportive care (eg fluid restriction and diuretics) affected these parameters.
Evaluation of organ failure and complications of highdose MP
Renal insufficiency was defined as doubling of the baseline pretransplant creatinine, and renal failure as a serum creatinine greater than 3 mg/dl or the need for hemodialysis. Respiratory failure was defined as requirement for ventilatory support. Known early toxicities of high-dose MP (including hyperglycemia, hypertension and fungal infections) and episodes of severe bleeding were evaluated in all patients from initiation of high-dose MP to day 100 post transplant or until death, whichever occurred first. Severe bleeding was defined as any bleeding associated with the transfusion requirement of у2 units of packed red blood cells over a 24 h interval.
Statistical considerations
Descriptive statistics (mean or median, and range) were used to analyze high-dose MP dose and duration, and serum bilirubin. Factors that may have influenced response to therapy with high-dose MP in responders and nonresponders were compared using the Fisher's exact test for categorical variables and the Kruskal-Wallis test for continuous variables. A logistic regression model was used to estimate the probability of fatal VOD based on the patient's total serum bilirubin and percent weight gain on the day high-dose MP was begun, as described by Bearman et al. 30 The calculated probability of dying from VOD in the responding and nonresponding patients was compared using the KruskalWallis test.
Results
Patient characteristics
From January 1994 to May 1998, 782 patients underwent bone marrow or stem cell transplantation at Washington University. The distribution of patients by source of stem cells was 499 autologous, 214 related donor and 69 unre-lated donor transplants. Twenty-eight of these 782 patients (3.6%) developed hepatic RRT characterized according to the Seattle criteria as VOD (n = 20) or LDUE (n = 8), and were treated with high-dose MP. All patients who developed hepatic RRT associated with bilirubin у4 mg/dl were treated with high-dose MP, and are included in this analysis. Of these, one patient developed hepatic RRT characterized by hyperbilirubinemia, tender hepatomegaly and severe fluid retention (10%) occurring 36 days after autologous transplantation for breast carcinoma, and was included in the VOD group.
Demographic characteristics, transplant information and risk factors for VOD for these 28 patients are shown in Table 1 . Five patients received low-dose heparin infusion (100 U/kg/day) 31 beginning with the preparative regimen as prophylaxis against hepatic RRT, due to the presence of pre-transplant risk factors (hepatitis B seropositivity, abnormal liver function tests).
Administration of high-dose MP
Treatment with high-dose MP was begun a mean of 9.7 days (median 8 days, range, 1-36 days) post transplant. The mean interval from onset of bilirubin у4 mg/dl to initiation of high-dose MP was 1 day (range, 0-4). The mean unit Bone Marrow Transplantation dose of high-dose MP administered was 1032 mg (range, 750-1800 mg). Two patients (both responders to high-dose MP) received unit doses of MP of 1000 mg/m 2 for a total of six doses, a protocol violation. When response to therapy was assessed at 10 days after initiation of high-dose MP, all but three patients (these three patients were responders to high-dose MP) continued to receive a tapering dose of MP.
Outcome of hepatic RRT after high-dose MP
When assessed 10 days after treatment with high-dose MP, 17 patients (61%) with hepatic RRT (12 patients with VOD, five patients with LDUE) responded. The total serum bilirubin in responding patients decreased from a mean of 8.6 mg/dl (median 7.5 mg/dl, range, 4-17.9) at the start of treatment to 4.1 mg/dl (range, 0.5-7.9) 10 days after the start of high-dose MP. The mean total serum bilirubin in the 11 nonresponding patients was 6.3 mg/dl (median 5.7 mg/dl, range, 3.1-10.2) at the start of high-dose MP, and 11.3 mg/dl (range, 4.5-25.6) 10 days after. Changes in mean total serum bilirubin relative to the start of high-dose MP for all 21 patients are shown in Figure 1 .
Three patients with VOD, which did not respond to highdose MP, were treated with PGE1 (0.3 ng/kg/min), as allowed in the protocol design, at 4, 7 and 9 days after completion of the high-dose MP. However, no improvement in VOD was observed in either of these patients. Three days after completion of high-dose MP, one other patient with an initial diagnosis of LDUE was treated with tPA (20 mg over 2 days) and heparin, without improvement. In violation of the study design, two patients (1 VOD, 1 LDUE) who responded to high-dose MP were treated with PGE1 (0.3 ng/kg/min administered for less than 36 h) concomitantly with high-dose MP. PGE1 was discontinued after recognition of the violation. 
Predictors of response to high-dose MP
When compared to the responding patients, non-responders had a lower pretransplant DLCOc (P = 0.04). A trend towards a higher amount of weight gain (P = 0.10) and the presence of 3 (vs 2 or less) Seattle criteria (P = 0.06) was observed in the non-responding patients. Among the variables analyzed, no other factor was able to differentiate responders from non-responders (Table 2) . Receipt of standard doses of MP (0.5-1.5 mg/kg/day) when treatment with high-dose MP was initiated did not influence response to high-dose MP (P = 0.42).
The probability of dying as a result of VOD at the time high-dose MP was initiated was estimated using a method of predicting fatal outcome developed by Bearman et al 30 for the 11 responding patients and the eight non-responding patients with VOD who began treatment on or before day 16 post transplant (the model's coefficients were calculated up to day 16 only). The mean probabilities of a fatal outcome were calculated based on total serum bilirubin and percent weight gain on the day high-dose MP was initiated and were 18% for responders and 23% for nonresponders. These probabilities were not significantly different (P = 0.30).
Complications of high-dose MP
Hyperglycemia (blood glucose Ͼ200 mg/dl) was observed in 27 patients (97%). None of these patients had prior diabetes mellitus or a known history of steroid-induced hyperglycemia. Two patients (7%), both allogeneic recipients, developed hypertension, which required pharmacologic intervention. Although two patients (7%) developed bleeding episodes after treatment with high-dose MP, the bleeding was not severe in either case.
Outcome
None of the 17 patients who responded to high-dose MP developed organ failure. Six nonresponders developed organ failure, which resulted in their death. Causes of death are shown in Table 3 . Three of the 28 patients (11%) treated with high-dose MP expired as a result of infection. Fungal Table 2 Characteristics of responding and nonresponding patients (mean ± s. infection was observed in two patients, both unrelated donor recipients: one patient with primary graft failure and the other patient with grade IV acute GVHD. At 100 days post transplant, all 13 surviving responders had a normal serum bilirubin and no evidence of hepatic RRT. One patient with VOD unresponsive to high-dose MP had normal serum bilirubin and no evidence of VOD on posttransplant day 100.
Discussion
This study reports on early treatment, with high-dose MP, of 28 stem cell transplant patients with hepatic RRT. The response rate, assessed 10 days after initiation of this treatment, was 61% overall, and 60% in those patients with VOD. Although no convincing data exist to support the concept that therapy administered to patients with VOD can alter the natural history of VOD or prevent progression to organ failure and death, early intervention may be an important determinant of the outcome of this syndrome. 27 Two reports suggested that success of therapy for VOD depended on early treatment. Goyal et al 32 To date, all clinical trials that have evaluated a therapeutic intervention for the management of established VOD, including the present study, have been non-controlled. Thus, it is difficult to determine the independent effects of these interventions. Many variables besides the therapeutic intervention may account for the outcomes observed, and present significant challenges in the design of prospective, controlled trials to determine the efficacy of agents given to treat VOD. These variables include the cri-741 Table 3 Causes of death occurring in the 14 patients who expired within 100 days post-transplant teria used to establish the diagnosis of VOD and other criteria for patient selection, supportive care strategies, response definitions, and co-morbid conditions that may confound the analysis. Of these variables, the criteria for the diagnosis of VOD may be the most important, given the controversy regarding the specificity and prognostic significance of these criteria. In this study, we used the Seattle criteria for the diagnosis of VOD. Although the Seattle criteria are practical and easily applied at the bedside and permit ready comparisons of patient characteristics from different institutions when strictly applied, some reports have challenged the specificity of the Seattle criteria in the diagnosis of VOD. Carreras et al 34 observed that the predictive value of the Seattle criteria depended on the number of criteria present at diagnosis. Using transjugular liver biopsy and measurement of hepatic venous pressure gradient to confirm the clinical diagnosis of VOD, eight of the 19 cases (42%) with two Seattle criteria present had histologic evidence of VOD in comparison to 10 of 11 cases (91%) suspected on the basis of three Seattle criteria. Although this study was prospective, the relatively small number of patients in each of the two cohorts was small and thus the data may not be generalized to be true for all patients with VOD without confirmation by other investigators. Blostein et al 35 observed a better prognosis in patients with one or two (vs three) Seattle criteria for VOD; however, this was a retrospective analysis and patient cohorts were small (ie only eight patients in the cohort with three Seattle criteria for VOD). A prospective study of large numbers of patients with VOD, confirmed by a gold standard method such as histologic features, will be required to better define the specificity and prognostic significance of the Seattle criteria in the diagnosis of this complication.
We, and others, have used the pace of the change in bilirubin as a surrogate marker for response to the therapeutic intervention given to patients with VOD. During the natural history of VOD managed with supportive care only, laboratory tests of liver dysfunction peak approximately 10 days after their initial rise and, in those whose VOD resolved, returned to baseline values approximately 10 days later. 1 In the cohort of responsive patients in our study, the serum bilirubin peaked 4 days on average after the initial rise, and declined significantly within 2 days of initiating treatment with HDM ( Figure 1) . Thus, based on comparisons to published data, it is unlikely that spontaneous improvement in hepatic RRT would have occurred this rapidly, without an effective intervention.
It is important to speculate whether favorable patient selection rather than treatment with high-dose MP may have resulted in the outcomes observed in this study. To date, only one model has used early clinical signs of VOD, ie total serum bilirubin and percent weight gain within 1-2 weeks of transplantation, to predict the probability of subsequent fatal outcome. 30 Applying this model to our data, the mean probabilities of fatal outcome were 18% for responders to high-dose MP and 23% for non-responders (P = 0.30). Therefore, this model predicted that the patients entered into this clinical trial had a substantial risk for mortality after the diagnosis of VOD, and were not uniformly destined to spontaneously improve with supportive measures alone. The predicted mortality of our patients with VOD also approximates the mortality actually observed in patients with moderate VOD described by McDonald et al. 4 In the latter study, the severity of VOD was determined retrospectively looking back from transplant day 100. The mortality of patients with VOD correlated with the severity of the syndrome, and was 9%, 23% and 98% for patients with mild, moderate and severe VOD, respectively. In our study none of 17 patients who responded to high-dose MP, and six of 10 (60%) of the non-responding patients expired as a result of progressive VOD. Although speculative, this discrepancy in actual vs predicted mortality in the patients with VOD responsive to high-dose MP may reflect efficacy of high-dose MP in reducing mortality. Alternatively, the model may be less accurate in the prediction of mortality when applied to patients with somewhat different characteristics (ie different preparative regimens, etc) than that of the patients from which the model was derived.
Low pretransplant DLCOc was the only variable found to be a significant prognostic factor for poor response to high-dose MP (P = 0.04). Matute-Bello et al 36 first reported the association between reduced diffusion capacity measured before transplantation and the risk of subsequent development of severe hepatic VOD. The pathogenesis of this association is unknown, although it is speculated that a decreased DLCOc might reflect pre-existing systemic endothelial damage and susceptibility to severe hepatic injury from high-dose therapy.
In this study, we observed by univariate analysis that the presence of three (vs less) Seattle criteria for VOD, at the beginning of high-dose MP may be a predictor of poor response to HDM (P = 0.06). This observation is in accordance with reports by Miniero et al 37 and Carreras et al. 34 The presence of weight gain, but not the absolute total serum bilirubin may also be another predictor of poor response to high-dose MP (P = 0.1). However, in our study, when the variables of weight gain and total serum bilirubin were collectively considered and weighted based on their individual importance by analysis using the logistic regression model, 30 the probability of a fatal outcome as predicted by this model would have been similar in the responders (18%) and the non-responders (23%) to highdose MP, with the difference being not statistically significant (P = 0.30). This points out the importance of not relying on any one variable (such as weight gain alone) in predicting the prognosis of patients with VOD. Also, this analysis demonstrates that one cannot state with confidence that the patients with VOD responsive to high-dose MP were a group with an inherently better prognosis than the non-responders, and who were destined to recover from hepatic RRT with or without high-dose MP.
It is of interest that 20 patients who received corticosteroids either in high doses during the preparative regimen or at conventional doses (0.5-1.5 mg/kg/day) for prophylaxis against GVHD post transplant (Table 1) subsequently developed hepatic RRT, and that 11 of these patients responded to treatment with high-dose MP. These observations suggest that factors such as timing of initiation of high-dose MP and the dose of MP administered may be important determinants of response of hepatic RRT to treatment with high-dose MP. Notably, administration of conventional doses of corticosteroids as prophylaxis against GVHD when treatment with high-dose MP was initiated did not influence response of hepatic RRT to this intervention.
Treatment of hepatic RRT with high-dose MP in transplant patients was generally well tolerated, with no serious sequelae documented. Transient steroid-induced hyperglycemia, observed in 96.5% of patients, was easily controlled with insulin. Hypertension and gastrointestinal bleeding, each observed in 7% of patients, may have been related to high-dose MP, but other factors could have contributed. Fungal infections were observed in two patients after initiation of high-dose MP and to day 100 of follow-up. Both patients were severely immunosuppressed from severe GVHD or primary graft failure and were thus at high risk for development of infections.
The published incidence of VOD varies among transplant centers, ranging from 3 to 53%. 1 This disparity relates to variables such as toxicity of different preparative regimens, patient selection, and definition of VOD. The incidence observed at our center (3.6%) was similar to the incidence reported in a prospective study from the EBMT registry. 38 Factors that may have contributed to the low incidence of hepatic RRT at our institution include a relatively small proportion of mismatched and unrelated donor transplants, the recent trend to using less intense preparative regimens, and probably the routine administration of prophylactic heparin for patients at high risk for hepatic RRT.
In this trial, most patients with hepatic RRT responded to intervention with high-dose MP, given in addition to supportive measures. However, patients with VOD and organ failure have a very poor prognosis. Bearman et al 27 reported a 29% response rate using tPA and heparin in the treatment of VOD, but observed a significant risk (23%) of severe hemorrhage. Richardson et al 39 reported results of treatment of 19 patients with VOD with defribrotide. Overall response rate to administration of defibrotide was 42%, and no significant toxicity was reported. Liver transplantation, although effective in some patients, 40, 41 is limited by the availability of a suitable donor liver. Surgical 42, 43 or transjugular [44] [45] [46] venous shunting in the treatment of VOD are promising, but invasive techniques in these patients at high risk of bleeding. Earlier intervention, and perhaps combinations of effective agents with differing mechanisms of action are worthy approaches to future investigations for treating patients with hepatic RRT. In considering the design of future clinical trials in this area, the low incidence of hepatic RRT observed at many institutions would make accrual to large randomized therapeutic trials difficult, if not impossible, to complete.
In conclusion, resolution of hepatic RRT occurred in the majority of patients in this study treated with high-dose MP; however, randomized, controlled trials or additional well designed confirmatory phase II studies, are required to determine the efficacy of high-dose MP for early treatment of hepatic RRT.
